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Abstract Recent investigations have suggested that
highly trained athletes may be less responsive to the
ergogenic effects of b-alanine (BA) supplementation than
recreationally active individuals due to their elevated
muscle buffering capacity. We investigated whether train-
ing status influences the effect of BA on repeated Wingate
performance. Forty young males were divided into two
groups according to their training status (trained: T, and
non-trained: NT cyclists) and were randomly allocated to
BA and a dextrose-based placebo (PL) groups, providing
four experimental conditions: NTPL, NTBA, TPL, TBA.
BA (6.4 g day-1) or PL was ingested for 4 weeks, with
participants completing four 30-s lower-body Wingate
bouts, separated by 3 min, before and after supplementa-
tion. Total work done was significantly increased following
supplementation in both NTBA (p = 0.03) and TBA
(p = 0.002), and it was significantly reduced in NTPL
(p = 0.03) with no difference for TPL (p = 0.73). BA
supplementation increased mean power output (MPO) in
bout 4 for the NTBA group (p = 0.0004) and in bouts 1, 2
and 4 for the TBA group (p B 0.05). No differences were
observed in MPO for NTPL and TPL. BA supplementation
was effective at improving repeated high-intensity cycling
performance in both trained and non-trained individuals,
highlighting the efficacy of BA as an ergogenic aid for
high-intensity exercise regardless of the training status of
the individual.
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Introduction
Carnosine (b-alanyl-L-histidine) is a cytoplasmic dipeptide
found in high concentrations in the skeletal muscle of
vertebrates and non-vertebrates, as well as in the central
nervous system. Carnosine may play multiple roles in
muscle, such as antioxidant (Boldyrev et al. 1993) and anti-
glycant (Hipkiss et al. 1995). In addition, recent studies
have shown that increased carnosine content in muscle
fibres may improve the Ca2? sensitivity of the contractile
apparatus and enhance Ca2? release from sarcoplasmic
reticulum when Ca2? release is inhibited, such as during
fatigue (Dutka et al. 2012). However, it is undisputed that
intramuscular pH buffering is a major function of carno-
sine, a consequence of the pKa of the imidazole ring of
carnosine being 6.83 (Bate-Smith 1938).
Harris et al. (2006) showed that b-alanine (BA) avail-
ability is the rate-limiting factor for carnosine synthesis in
skeletal muscle and that b-alanine supplementation is able
to increase the intramuscular content of carnosine. After
this seminal study by Harris and colleagues, several
investigations have examined the ergogenic effects of b-
alanine supplementation on exercise performance and
capacity [for a review, see Sale et al. (2013)] and a recent
meta-analysis concluded that supplementation significantly
improves exercise capacity, but not sport-related
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performance (Hobson et al. 2012). The body of evidence
surrounding the ergogenic effects of b-alanine supple-
mentation is increasing; however, the majority of studies
that have shown a positive effect have used recreationally
active participants. Although some studies have shown
positive effects of b-alanine on trained athletes (Tobias
et al. 2013; Salles Painelli et al. 2013; Van Thienen et al.
2009; Derave et al. 2007), several investigations have
shown no improvements or marginal effects (Derave et al.
2007; Baguet et al. 2010; Saunders et al. 2012; Hobson
et al. 2013; Ducker et al. 2013; Chung et al. 2012; Howe
et al. 2014). As such, the ergogenic effects of b-alanine in
athletes are less clear than in non-trained individuals. In
addition, some authors speculate that athletes might be less
responsive to b-alanine supplementation (Bellinger et al.
2012; Bellinger 2014).
It has been shown that trained athletes have an ele-
vated muscle buffering capacity as an adaptation to
exercise training (Weston et al. 1997; Edge et al. 2006a,
b). Since most studies that recruited athletes have failed
to demonstrate an ergogenic effect of b-alanine, it has
been speculated that this may be due to the already
increased buffering capacity in highly trained individuals,
limiting the measurable effect of increased carnosine
content through b-alanine supplementation (Bellinger
et al. 2012; Bellinger 2014). Although athletic popula-
tions are likely to be the most interested in the ergogenic
effects of b-alanine, it remains unclear to what extent
these highly trained individuals can benefit from sup-
plementation. No study to date has directly compared
whether athletes respond differently to b-alanine sup-
plementation in comparison to non-trained recreationally
active individuals.
Therefore, to gather knowledge on the potential differ-
ential responses to b-alanine supplementation between
trained and non-trained participants, the aim of this study
was to investigate whether training status influences the
ergogenic effect of b-alanine supplementation on repeated




Forty young male individuals participated in this study.
They were allocated to two groups according to their
training status (endurance-trained cyclists: N = 20; non-
trained individuals: N = 20). Participants were further
randomly allocated to the b-alanine and placebo (PL)
groups, matched for total work done (TWD) measured
during the habituation session. One trained cyclist with-
drew from the study due to injury, meaning that 19 trained
cyclists were included in the final data set. The cyclists
were all actively involved in structured training programs
and, although endurance training formed a large part of
their training routine, all athletes also undertook regular
sprint training. Thirteen of these athletes were competing at
national level and the remaining six athletes were partici-
pating in state-level official competitions at the time of data
collection. The non-trained participants were recreationally
active individuals who engaged in a variety of activities
(e.g., weightlifting, running, team sports) 1–3 times per
week. Participant characteristics, experience and weekly
training volumes at the moment they initiated the study are
presented in Table 1. The ability to perform high-intensity
intermittent exercise was clearly different between the
trained and the non-trained groups (Table 2).
Participants were required not to have taken any creatine
supplement for 3 months prior to the study and had not
taken b-alanine for at least 6 months prior to the study.
Participants were also requested to maintain similar levels
of physical activity and dietary intake for the duration of
the study and compliance with this request was verbally
confirmed with participants prior to commencement of the
study. Participants were fully informed of any risks and
discomforts associated with the study before completing a
health screen and providing written consent. The study was
approved by the Ethical Advisory Committee from the
School of Physical Education and Sport, University of Sao
Paulo (Approval Number: 2011/15).
Table 1 Participant characteristics
NTPL (N = 10) NTBA (N = 10) TPL (N = 9) TBA (N = 10)
Age (years) 26 ± 4 25 ± 4 33 ± 12 32 ± 8
Body mass (kg) 72.6 ± 8.8 77.6 ± 9.9 68.9 ± 10.0 71.7 ± 5.5
Height (m) 1.75 ± 0.08 1.80 ± 0.07 1.79 ± 0.07 1.82 ± 0.05
Weekly training volume (km) – – 230 ± 165 278 ± 94
Training experience (years) – – 9 ± 6 8 ± 8
NTPL non-trained ? PL, NTBA non-trained ? BA, TPL trained ? PL, TBA trained ? BA. No differences were observed between groups
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Experimental design
Participants attended the laboratory on three separate
occasions. The first visit was for protocol habituation, with
the remaining two visits for the completion of the main
trials. One main trial was completed before and one main
trial following a 4 week double-blind supplementation
period of either b-alanine or placebo. As such, the study
comprised four experimental conditions: non-
trained ? placebo (NTPL, N = 10), non-trained ? b-ala-
nine (NTBA, N = 10), trained ? placebo (TPL, N = 9)
and trained ? b-alanine (TBA, N = 10).
Participants were supplemented for 4 weeks with either
6.4 g day-1 BA (CarnoSynTM, Compound Solutions
Inc.TM, CA, USA) or an equivalent amount of placebo
capsules (dextrose; Ethika Inc.TM, Sa˜o Paulo, Brazil). This
dosing regimen has been proven to be effective in
increasing muscle carnosine content over 2 (Stellingwerff
et al. 2012) and 4 weeks (Harris et al. 2006), and it is
*10–20 times higher than the average b-alanine intake
from food, as calculated for the participants of the present
study (results are shown in Table 3). The participants took
two 800-mg gelatin capsules four times per day at 3–4 h
intervals. Carboxymethyl cellulose was added to the b-
alanine capsules (100 mg per 800 mg of b-alanine) in
order to slow the absorption of b-alanine and minimize
paraesthesia. Participants received exactly 4 weeks’ worth
of supplement in a sealed, unmarked container, and com-
pliance was monitored by verifying the remaining contents
of the container upon return to the lab following the sup-
plementation period. The degree of compliance was
reported to be 100 % in all groups.
Experimental procedures
Preliminary testing
Height and body mass were recorded upon arrival at the
laboratory. The exercise protocol required participants to
complete 4 bouts of a modified lower-body cycling Win-
gate test (Inbar and Bar-Or 1986), using a specifically
designed ergometer (Biotec 2100, Cefise, Brazil). The
position on the cycle ergometer was determined prior to the
habituation session, recorded and maintained for all sub-
sequent trials. The participants’ feet were securely attached
to the pedals using toe clips and straps. Participants
warmed up for 5 min on the ergometer prior to the first
bout, against no resistance. On completion of the warm up,
the test began immediately from a static start. Each Win-
gate bout lasted 30 s and participants were required to
cycle against a load set at 5 % of body mass, which was
measured with a digital scale to the nearest 10 g. This 5 %
load was chosen over the original 7.5 % load in order to
allow the non-trained participants to complete the entire
4-bout protocol. Bouts were interspersed by 3-min passive
recovery, with all the participants being seated during this
recovery period. Standardised verbal encouragement was
given throughout every bout. Upon completion of the test,
the resistance was removed and the participants were
instructed to continue cycling at a self-selected cadence to
facilitate recovery. A set of 24 sensors measured wheel
velocity, with power output being calculated automatically
every second by computer software (Ergometric 6.0, Cef-
ise, Brazil). Mean power (MPO, W) and peak power (PPO,
W) output were obtained for each bout and TWD (J) was
obtained for the overall test session. Performance decre-
ment was measured as the percentage loss in work done
from the 1st to the 4th bout. The coefficient of variation for
TWD in the non-trained and the trained groups was
2.42 ± 1.86 and 1.78 ± 1.27 %, respectively.







TWD (J) 49,093 ± 6,043 54,399 ± 6,603 0.013
Performance
decrement (%)a
32.66 ± 7.38 11.93 ± 6.39 \0.0001
Relative peak power output
1st bout (W/kg) 8.18 ± 0.70 8.16 ± 0.77 0.940
2nd bout (W/kg) 7.73 ± 0.59 8.03 ± 0.80 0.196
3rd bout (W/kg) 6.89 ± 0.71 7.79 ± 0.69 \0.0001
4th bout (W/kg) 5.99 ± 0.87 7.50 ± 0.66 \0.0001
Relative mean power output
1st bout (W/kg) 6.67 ± 0.46 6.86 ± 0.51 0.238
2nd bout (W/kg) 5.74 ± 0.42 6.54 ± 0.52 \0.0001
3rd bout (W/kg) 4.93 ± 0.52 6.29 ± 0.50 \0.0001
4th bout (W/kg) 4.48 ± 0.53 6.04 ± 0.51 \0.0001
a Decrement in work done from the 1st bout to the 4th bout
Table 3 Energy, macronutrient
and b-alanine intake
NTPL (N = 10) NTBA (N = 10) TPL (N = 9) TBA (N = 10)
Energy (Kcal) 2,747 ± 661 3,364 ± 662 3,181 ± 430 2,511 ± 769
Carbohydrate (g) 342 ± 96 448 ± 86 364 ± 50 304 ± 64
Protein (g) 134 ± 37 150 ± 39 140 ± 42 111 ± 39
Fat (g) 94 ± 35 108 ± 47 129 ± 23 95 ± 52
b-Alanine (mg) 383 ± 191 397 ± 192 446 ± 328 364 ± 283
b-Alanine on trained and non-trained athletes 1209
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Main trials
Participants were requested to abstain from alcohol and
strenuous exercise in the 24-h period prior to the main
trials. Participants arrived at the laboratory in at least 2 h
following their last meal, and immediately began their
warm up followed by the 4-bout lower-body cycling
Wingate test. Ad libitum water consumption was allowed
during the main trials. To control for intervening variables,
food intake was assessed during the supplementation per-
iod by means of three 24-h dietary recalls undertaken on
separate days (2 weekdays and 1 weekend day), with the
aid of a visual photo album of real-sized foods and por-
tions. Nutritional supplements were also recorded. Energy
and macronutrient intakes were analysed by the software
Virtual NutriTM (Sa˜o Paulo, Brazil). The intake of b-ala-
nine from fish and red meats containing carnosine and its
related derivatives was estimated from the data of Jones
et al. (2011).
Statistical analyses
All data are presented as mean ± SD and were analysed
using the SAS statistical package, (SAS version 9.2). A
one-way ANOVA, with Group (i.e. NTPL, NTBA, TPL
and TBA) as a fixed factor, was used to compare the par-
ticipant characteristics and baseline performance between
groups. The mixed models for repeated measures were
used to examine the effect of supplementation on TWD,
with Group and Time (i.e. pre-supplementation, post-sup-
plementation) as fixed factors. To mitigate the impact of
inter-individual data variability, all TWD values were
converted into delta scores (i.e., POST-PRE values) and
thereafter tested by a mixed model assuming ‘‘pre values’’
as a covariate. The mixed models were also performed to
examine the effect of supplementation on MPO and PPO,
with Group, Time and Bout (i.e. bout 1, bout 2, bout 3, bout
4) as fixed factors. Tukey tests were used for post hoc
analyses and effect sizes were calculated using Cohen’s d.
Statistical significance was accepted at p B 0.05, with a
trend towards significance being accepted at p B 0.1.
Results
Wingate test
Effects of b-alanine supplementation regardless of training
status
There was no difference in TWD between placebo and b-
alanine groups prior to supplementation (placebo:
50,773 ± 7,349 J; b-alanine: 52,538 ± 6,283 J;
p = 0.44). There was a significant interaction effect of
Group 9 Time on TWD (F = 16.48; p = 0.0002); fol-
lowing supplementation, TWD was increased by
1,663 ± 1,457 J in the b-alanine group (p = 0.0004) and
decreased by 832 ± 2,308 J in the placebo group
(p = 0.07; Fig. 1a). A total of 17 out of the 20 participants
supplemented with b-alanine improved TWD following
supplementation; 8 out of the 10 participants in the NTBA
improved their performance, while 9 out of the 10 in the
TBA group showed improved performance (Fig. 2a). On
the other hand, only 10 out of the 19 participants supple-
mented with placebo improved TWD following supple-
mentation; 5 out of the 10 participants in the NTPL
improved their performance, while 5 out of the 9 in the
TPL group showed improved performance (Fig. 2b).
Effects of b-alanine supplementation in trained versus non-
trained subjects
Prior to supplementation, performance decrement from the
1st to the 4th Wingate bout was 32.3 ± 6.6 and
33.1 ± 8.5 % for the NTPL and the NTBA groups,
respectively, with no differences between these two groups
(p [ 0.05). For the trained athletes, prior to the supple-
mentation period, the performance decrement in the Win-
gate was 11.6 ± 7.9 and 12.3 ± 5.0 % for the TPL and the
TBA, respectively (p [ 0.05). Performance decrement for
Fig. 1 a Absolute change in performance in placebo (PL) and b-
alanine (BA) with trained and non-trained participants grouped
together. *p B 0.001 from placebo. b Absolute change in perfor-
mance for individual groups NTPL, TPL, NTBA and TBA.
#p = 0.008 from NTPL. $p = 0.037 from TPL. Effect sizes:
NTPL—0.2; TPL—0.03; NTBA—0.2; TBA—0.4
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the NTPL and the NTBA groups was significantly higher
when compared with both the TPL and the TBA groups (all
p \ 0.05).
TWD did not differ within the non-trained (NTPL:
47,913 ± 5,313 J and NTBA: 50,274 ± 6,765 J;
p = 0.43) and trained groups (TPL: 53,951 ± 8,258 J and
TBA: 54,802 ± 5,119 J; p = 0.78) prior to supplementa-
tion. TWD was significantly increased following supple-
mentation in both the NTBA (?1,349 ± 1,411 J;
p = 0.03) and TBA groups (?1,978 ± 1,508 J;
p = 0.002), and it was significantly reduced in the NTPL
(-1,385 ± 2,815 J; p = 0.03) with no significant differ-
ence being shown in the TPL group (-219 ± 1,507 J;
p = 0.73). Analysis of covariance revealed that absolute
change in TWD in both supplemented groups was signifi-
cantly higher than in their respective placebo groups
(NTBA vs. NTPL: p = 0.008; TBA vs. TPL: p = 0.037).
However, no significant differences were shown between
groups (NTPL vs. TPL: p = 0.10; NTBA vs. TBA:
p = 0.60) indicating that the effect of b-alanine supple-
mentation was not affected by training status (Fig. 1b).
MPO was reduced in each subsequent bout during the
pre-supplementation trial for all of the groups (Fig. 3).
There was an interaction effect on MPO (Group 9 -
Time 9 Bout, F = 4.89; p \ 0.0001); post hoc tests
revealed that both supplemented groups (i.e. NTBA and
TBA) were able to maintain MPO from bouts 3–4 fol-
lowing supplementation (both p [ 0.05). Compared to the
pre-supplementation trial, post-supplementation MPO was
higher in bout 4 for the NTBA (p = 0.0004), and higher in
bouts 1, 2 and 4 for the TBA group (p B 0.05, Fig. 3).
In the pre-supplementation test, both of the non-trained
groups (i.e. NTPL and NTBA) showed a significant
reduction in PPO in every subsequent trial (all p \ 0.05).
Conversely, both trained groups were able to maintain PPO
across bouts pre-supplementation (all p [ 0.05). Impor-
tantly, there was an interaction effect on PPO (Group 9 -
Time 9 Bout, F = 2.70; p = 0.003), with increased
values shown post-supplementation in bout 4 for the NTBA
(p = 0.004); and a tendency for increased values in bout 2
for the TBA group (p = 0.08).
Food intake
The energy, carbohydrate, protein, fat and b-alanine intake
are presented in Table 3. No significant differences were
observed within or between groups (all p [ 0.05).
Blinding efficacy and side effects
Of the 20 participants who were supplemented with b-
alanine, only 4 were able to correctly guess their supple-
ment. Of the 19 participants who were supplemented with
dextrose, only 9 were able to correctly guess their sup-
plement (Fischer exact test: p = 0.33). Three participants
taking b-alanine reported mild paraesthesia and were able
to correctly identify their supplement. We reanalysed the
data without these three participants and the results
remained similar, with no significant differences in the
overall findings (as such, these data are not shown). No
side effects related to dextrose ingestion were reported.
Discussion
Since there is the possibility that an already increased
muscle buffering capacity explains the lack of a measur-
able ergogenic effect of b-alanine in trained athletes, we
chose, for the first time, to directly investigate whether
training status influences the ergogenic effect of b-alanine
supplementation. The main findings of this study were that
b-alanine supplementation improved repeated-bout high-
Fig. 2 a Individual response in TWD to supplementation in the b-
alanine groups (NTBA and TBA, respectively). b Individual response
in TWD to supplementation in the placebo groups (NTPL and TPL,
respectively). Individuals who improved performance are indicated
by a solid line, while those who did not are indicated by a dotted line
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intensity cycling performance, to a similar extent, in both
trained and non-trained participants.
The findings of our study are in contrast to previous
studies that have shown no effect of b-alanine on highly
trained individuals (Derave et al. 2007; Baguet et al. 2010;
Bellinger et al. 2012; Saunders et al. 2012). The differences
in results might be due to the protocols employed; previous
studies may not have used exercise tests of sufficient
intensity or duration to be influenced by decreased intra-
muscular pH, or may have been susceptible to pacing
strategies, masking any ergogenic effects of increased
muscle buffering capacity. Intermittent supra-maximal
exercise promotes a considerably greater intramuscular
acidosis than continuous high-intensity exercise (Herman-
sen and Osnes 1972; Belfry et al. 2012), probably because
the former is more reliant on glycolytic ATP resynthesis
(Belfry et al. 2012). Thus, it is reasonable to assume that
intermittent exercise performance is more likely to be
limited by muscle acidosis and, hence, more susceptible to
improvements with increased buffering capacity. The
4-bout lower-body modified Wingate test is extremely
high-intensity in nature and requires the individual to
perform maximally in every bout. Artioli et al. (2007) and
De Salles Painelli et al. (2014) showed blood lactate values
up to *15 mmol L-1 following the 4-bout upper-body
Wingate test and venous blood pH as low as *7.05 fol-
lowing 3 bouts of the upper-body Wingate test, highlight-
ing the relevant contribution of anaerobic glycolysis for
tests similar in duration, number of bouts and recovery
between bouts. Therefore, the repeated-bout Wingate test
would appear to be an appropriate model to detect per-
formance improvements promoted by nutritional strategies
that increase buffering capacity.
In the present study, TWD did not differ within the non-
trained (NTPL vs. NTBA) and trained groups (TPL vs.
TBA) prior to supplementation, indicating that randomi-
sation successfully generated similar groups in each profile.
Moreover, TWD prior to supplementation in the trained
participants was *11 % higher (p \ 0.05) than in the non-
trained participants, and work decrement from the 1st to
the 4th bout in the non-trained participants was 20 %
higher than in their trained counterparts (average 32 vs.
12 % decrement, respectively; p \ 0.05). Since it has been
demonstrated that the buffering capacity of homogenates of
muscle (which is assumed to be a measure of muscle
buffering capacity in situ) is related to repeated sprint
ability and work decrement over repeated sprints (Bishop
et al. 2004), it is plausible to assume that individuals in the
trained groups have higher muscle buffering capacity than
those in the non-trained groups. This, however, was not
directly measured in the present investigation because it
would require muscle biopsies, which are excessively
invasive to be performed in athletes in the middle of the
competitive season.
It should be noted that the peak and mean power
attained in the 1st bout were not different between trained
and non-trained. However, this was most likely caused by
the lowered mechanical load of the Wingate test (5 % in
Fig. 3 MPO during each bout
of the Wingate test for NTPL
(a), NTBA (b), TPL (c), and
TBA (d). Pre- and post-
supplementation MPO are
indicated by white and black
bars, respectively. *p B 0.05
from the previous bout.
#p B 0.05 from pre-
supplementation during the
same bout
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the present study instead of the original 7.5 %) employed
in our protocol, which hampered the Wingate test to dis-
tinguish the trained from the non-trained participants. On
the other hand, this modification was necessary to allow the
untrained individuals to complete the entire 4-bout proto-
col, which would not be possible for most of them if we
used the 7.5 % load. In spite of the lack of differences in
the first bout, our 4-bout modified Wingate test was able to
clearly differentiate both groups in terms of mean and peak
power in the last 2–3 bouts, TWD in the overall protocol
and performance decrement over the 4 bouts.
Despite the remarkable differences in repeated sprint
ability between the trained and non-trained individuals,
four weeks of b-alanine supplementation increased TWD
to a similar extent in both groups (non-trained:
2.52 ± 2.64 %, trained: 3.64 ± 2.87 %). The magnitude
of the improvement in performance observed in the
present study is in agreement with a recent meta-analysis
that showed a 2.85 % positive effect of b-alanine
(Hobson et al. 2012). Although improvements in TWD
around 3.0 % may suggest only a discrete effect, it is
worth noting that TWD in the trained participants was
*11 % higher than in their non-trained counterpart,
meaning that 4 weeks of supplementation elicited a
performance improvement which represents about one-
third of the improvement achieved by several years of
training.
In the present study, TWD increased due to an increased
ability to maintain MPO during the Wingate bouts. A
beneficial effect can be expected in the latter bouts of the
test, since a single 30-s maximal effort is unlikely to be
affected by reduced intramuscular pH (Bogdanis et al.
1998). Artioli et al. (2007) employed an upper-body
Wingate protocol to determine the effect of increased
extracellular buffering and showed an increase in MPO in
the last bout of exercise when experienced judo athletes
were supplemented with sodium bicarbonate. Similarly, the
non-trained participants supplemented with b-alanine in
this study improved their MPO in the final bout of exercise,
likely due to an increase in muscle buffering capacity over
the exercise pH transit range, from increased carnosine
concentrations. However, the trained participants supple-
mented with b-alanine showed an improved MPO across
almost all of the bouts. This may be due to the training
status of the trained athletes, who are likely to have had an
increased ability to consistently perform maximal exercise
across each bout, resulting in an earlier intramuscular H?
accumulation, placing an earlier reliance on their buffering
capacity. Furthermore, it is possible that b-alanine sup-
plementation provided a higher training quality during the
supplementation period, enhancing training volume and/or
intensity, thus increasing MPO in almost all of the bouts in
TBA.
A potential limitation of this study is that we were
unable to perform muscle analyses to confirm the efficacy
of b-alanine in increasing muscle carnosine content.
However, all human studies using 1.6–6.4 g day-1 of b-
alanine for 4 weeks or longer have so far reported increases
of at least 8 mmol kg-1 dry muscle (corresponding to an
increase of 40 % in muscle carnosine) (Sale et al. 2013).
According to the estimates by Harris et al. (2006), a 40 %
increase in muscle carnosine would represent a *4 %
increase in whole muscle buffering capacity and a *5 %
in type II fibres buffering capacity. Considering that all
human studies with b-alanine supplementation have shown
increased muscle carnosine, it appears to be safe to assume
that our b-alanine supplementation protocol resulted in
increased muscle carnosine. Also, based on the current
findings showing that trained and non-trained participants
equally improved their performance, it is reasonable to
assume that carnosine accrual after b-alanine supplemen-
tation is not influenced by training status and training
history. This is in agreement with Kendrick et al. (2009)
using the same supplementation protocol as used in the
present study and where the carnosine content of types I
and II muscle fibres was measured directly, but in contrast
with a recent study by Bex et al. (2014). The latter study,
based on MRS measurements, suggested that carnosine
elevation induced by b-alanine is higher in trained as
compared to non-trained muscles. Further studies directly
comparing the responses of both trained and non-trained
individuals to b-alanine supplementation and its effects on
performance and muscle carnosine content in different
muscle fibre types are needed to clarify this issue.
It is important to note that 3 out of 20 of the participants
ingesting b-AThe energy, carbohydrate, protein, fat and b-
alaninelanine reported mild paraesthesia, which is a
symptom commonly described when a single dose of
1,600 mg is ingested (Harris et al. 2006; De´combaz et al.
2012). The same symptoms are not observed when
1,600 mg of b-alanine is provided in controlled release
tablets (Saunders et al. 2012; De´combaz et al. 2012),
suggesting that the strategy adopted in our study to slow
the absorption of b-alanine (i.e., the addition of carboxy-
methyl cellulose added to the gelatin capsules) was not
totally successful in preventing paraesthesia. Despite this,
our data show that the participants as a group were not able
to correctly guess the substance that they were ingesting,
indicating that the blinding of the present study remained
intact.
It can be concluded that 4 weeks of b-alanine supple-
mentation improved repeated high-intensity cycling per-
formance in both trained and non-trained participants. The
findings of the present study indicate the efficacy of b-
alanine as an ergogenic aid for high-intensity intermittent
exercise regardless of the training status, highlighting that
b-Alanine on trained and non-trained athletes 1213
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highly trained athletes can benefit from the use of b-
alanine.
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